Opendata, web and dolomites

TRS SIGNED

A paradigm change in the treatment of blinding ocular diseases

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 TRS project word cloud

Explore the words cloud of the TRS project. It provides you a very rough idea of what is the project "TRS" about.

2028    launch    corticosteroids    broad    disrupt    tarsius    worldwide    700    molecule    treating    diseases    indication    perform    autoimmune    steroid    gain    capability    excellent    iia    market    financing    society    inflammation    shares    platform    exclusivity    array    relieve    medical    patients    class    expand    risk    post    exceed    candidate    tax    therapeutic    requiring    hundreds    global    profits    causes    billion    us    reliefs    treatment    saving    pipeline    ocular    bio    secure    extended    engineer    devastating    itself    company    correspond    effect    revenue    drug    steroids    glaucoma    approved    clinical    lasting    reinvested    trial    commercialization    preclinical    impose    economic    local    shorter    500    immune    safe    mechanism    people    unmet    treat    2024    gt    infectious    disease    inspired    symptoms    blindness    penetration    believe    selecting    inflammatory    burden    merely    strategy    re    25    uveitic    first    urgent    orphan    grant    millions    time   

Project "TRS" data sheet

The following table provides information about the project.

Coordinator
TARSIUS PHARMA LTD 

Organization address
address: 19 YAHALOM ST.
city: ZICHRON YAAKOV
postcode: 3093765
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Israel [IL]
 Total cost 3˙461˙500 €
 EC max contribution 2˙423˙050 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-2
 Funding Scheme SME-2
 Starting year 2019
 Duration (year-month-day) from 2019-07-01   to  2021-06-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    TARSIUS PHARMA LTD IL (ZICHRON YAAKOV) coordinator 2˙423˙050.00

Map

 Project objective

Ocular inflammatory diseases – affecting hundreds of millions of people worldwide – impose a significant medical and economic burden on society and can lead to blindness. Today, corticosteroids are the most common method used to treat ocular non-infectious inflammation of any kind. Rather than treating the disease itself, however, steroids merely relieve its symptoms, and long-term use can result in devastating consequences. Our bio-inspired drug candidate is a non-steroid. It approaches inflammatory diseases from within the immune system and was developed to ‘re-engineer’ the immune system. Based on excellent preclinical results, we believe that this approach will have the capability to disrupt the immune mechanism that causes the disease in order to provide patients with a safe and long-lasting therapeutic effect, with the goal of saving them from blindness. Our platform technology has the potential to effectively treat a broad array of autoimmune and inflammatory diseases and to become a first in class, market approved molecule for local treatment of inflammatory ocular diseases. Our first target indication is uveitic glaucoma – a devastating orphan disease requiring urgent treatment and carrying high risk of blindness. Selecting an orphan indication as a market penetration strategy will grant us extended market exclusivity, tax reliefs and shorter time to market. In the project, we will perform a Phase I/IIa clinical trial. We will exploit the trial results to secure financing for further clinical development towards commercialization. The global ocular inflammation treatment market is expected to exceed more than US$ 500 Billion by 2024. As our first target indication has a significant unmet need with no approved treatment, we expect to gain 25% of market shares 5 years post launch, which would correspond to >€700 M in revenue for Tarsius in 2028 for uveitic glaucoma only. Profits will be reinvested to develop our product pipeline and expand our company.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "TRS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "TRS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

DNA DS (2019)

DNA Data storage

Read More  

ERGOVIAkinematix (2018)

New wearable measurement devices for Industry 4.0 based on gaming motion-capture system

Read More  

LiCrete (2018)

LiCrete - Light transmitting composite material for building purposes

Read More